Get started
Work

Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Year: 2017
Type: article
Abstract: Background: Myelofibrosis (MF) is a myeloproliferative neoplasm that is characterized by significant scar tissue and fibrosis in the bone marrow, enlarged spleen and/or liver from extramedullary hematopoiesis, and may include significant constitutional symptoms. The only curative therapy is allogeneic stem cell transplant. We sought to monitor QoL in patients undergoing HCST for MF.
DOI: 10.1016/j.bbmt.2016.12.402
Authors: Jeanne Palmer, Veena Fauble, Holly Geyer, Heidi Kosiorek, Amylou Dueck, Ruben A. Mesa, Tania Jain
Institutions: Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Banner Health, Mayo Clinic, Wayne State University, Detroit Medical Center
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2589514484
FWCI:
Cites:
Cited by:
Related to: 10